source
- Reverse mergers surge as biotech firms seek public listings via shell companiesReverse mergers, once dismissed, are now a common route for biotech startups to gain a public listing by merging with shell companies. Data from JB Strategy Partners shows roughly two dozen such d…
- FDA proposes 50% fee cut for US early-stage trials, but industry says speed matters moreThe FDA announced a proposal to cut the application fee by half for drugs that run their early-stage trials in the United States. The reduction, about $2.3 million at current rates, is intended to…